Abstract: The invention discloses a method of preparing a high chiral purity lactam intermediate D comprising a step of reducing a compound C to lactam intermediate D in a solvent by hydrogenation reduction using a heavy metal catalyst and a chiral inducer. Brivaracetam can be prepared in a single step using the lactam intermediate D. The synthesis route is short, reaction conditions are mild, post-treatment is simple, reaction yield is high, chiral selectivity is good, and production cost is low. The conversion rate of the compound C in the reaction is 81%, and the DE value of the compound D is more than 99.0%, which is suitable for industrial production.

Abstract: The invention discloses a method of preparing a high chiral purity lactam intermediate and brivaracetam. The invention provides a method of preparing a lactam intermediate compound represented by molecular formula D, the method comprising a step of reducing a compound C to a lactam intermediate D in a solvent by hydrogenation reduction using a heavy metal catalyst and a chiral inducer. Brivaracetam can be prepared with a single step using the lactam intermediate compound represented by molecular formula D of the present invention. The synthesis route is short, reaction conditions are mild, post-treatment is simple, reaction yield is high, chiral selectivity is good, and production cost is low. The conversion rate of the compound C in the reaction is 81%, and the DE value of the compound D is more than 99.0%, which is suitable for industrial production.

Abstract: Disclosed are amide compounds, preparation method and uses thereof, specifically, the compounds represented by formula I or pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, Q, X and n are defined as in the description. Also disclosed are a method for preparing the compounds of formula I, a composition containing the compounds, and the uses of the same in the preparation of medicaments for regulating blood lipid and/or preventing gallstone. The compounds of formula I disclosed in the present invention have stability in vitro, good solubility in the pharmaceutical organic solvents and favorable bioavailability in animals.

Abstract: A segment-assembled type pier column member with a steel-concrete composite structure includes a reinforcement tube embedded in a pile cap, wherein the reinforcement tube is connected with a bottom of a lower segment of a hollow steel tube pier and is poured with concrete, and pier columns in upper and lower segments are reinforced by means of segment connecting and being embedded with local reinforcing meshes. A steel cross beam is connected with an upper segment of the hollow steel tube pier in an assembled way. A pre-stressed tensioning duct is reserved between the steel cross beam and the pier column in the upper segment.

Abstract: A segment-assembled type pier column member with a steel-concrete composite structure includes a reinforcement tube embedded in a pile cap, wherein the reinforcement tube is connected with a bottom of a lower segment of a hollow steel tube pier and is poured with concrete, and pier columns in upper and lower segments are reinforced by means of segment connecting and being embedded with local reinforcing meshes. A steel cross beam is connected with an upper segment of the hollow steel tube pier in an assembled way. A pre-stressed tensioning duct is reserved between the steel cross beam and the pier column in the upper segment.

Abstract: Disclosed are amide compounds, preparation method and uses thereof, specifically, the compounds represented by formula I or pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, Q, X and n are defined as in the description. Also disclosed are a method for preparing the compounds of formula I, a composition containing the compounds, and the uses of the same in the preparation of medicaments for regulating blood lipid and/or preventing gallstone. The compounds of formula I disclosed in the present invention have stability in vitro, good solubility in the pharmaceutical organic solvents and favorable bioavailability in animals.